Compounds for treating amyloidoses
AssigneeAffiris AG
InventorsMarkus Mandler, Radmila Santic, Harald Weninger, Edith Kopinits
Life of this patent
Estimating the term…
Abstract
The present invention relates to the use of mimotopes in the treatment of β-Amyloidoses including but not limited to Alzheimer's disease, whereby said mimotopes are able to induce the in vivo formation of antibodies directed to non truncated Aβ1-40/42, and N-terminally truncated forms AβpE3-40/42, Aβ3-40/42, Aβ11-40/42, AβpE11-40/42 and Aβ14-40/42 without interfering with physiological functions of APP signalling.
Claims4
An isolated peptide consisting of an amino acid sequence selected from the group consisting of SHTRLYF(C) (SEQ ID NO:
- 59), SGEYVFH(C) (SEQ ID NO:
- 66), SGQLKFP(C) (SEQ ID NO:
- 67), SGQIWFR(C) (SEQ ID NO:
- 68), SGEIHFN(C) (SEQ ID NO:
- 69), GQIWFIS(C) (SEQ ID NO:
- 76), NDAKIVF(C) (SEQ ID NO:
- 104), GQIIFQS(C) (SEQ ID NO:
- 77), GQIRFDH(C) (SEQ ID NO:
- 78), HMRLFFN(C) (SEQ ID NO:
- 60), GEMWFAL(C) (SEQ ID NO:
- 79), GELQFPP(C) (SEQ ID NO:
- 80), GELWFP(C) (SEQ ID NO:
- 70), SHQRLWF(C) (SEQ ID NO:
- 61), HQKMIFA(C) (SEQ ID NO:
- 62), GEMQFFI(C) (SEQ ID NO:
- 81), GELYFRA(C) (SEQ ID NO:
- 82), GEIRFAL(C) (SEQ ID NO:
- 83), GMIVFPH(C) (SEQ ID NO:
- 84), GEIWFEG(C) (SEQ ID NO:
- 71), GEIYFER(C) (SEQ ID NO:
- 72), AIPLFVM(C) (SEQ ID NO:
- 101), GDLKFPL(C) (SEQ ID NO:
- 85), GQILFPV(C) (SEQ ID NO:
- 86), GELFFPK(C) (SEQ ID NO:
- 87), GQIMFPR(C) (SEQ ID NO:
- 88), HMRMYFE(C) (SEQ ID NO:
- 63), GSLFFWP(C) (SEQ ID NO:
- 89), GEILFGM(C) (SEQ ID NO:
- 90), GQLKFPF(C) (SEQ ID NO:
- 91), KLPLFVM(C) (SEQ ID NO:
- 102), GTIFFRD(C) (SEQ ID NO:
- 92), THQRLWF(C) (SEQ ID NO:
- 64), GQIKFAQ(C) (SEQ ID NO:
- 93), GTLIFHH(C) (SEQ ID NO:
- 94), GEIRFGS(C) (SEQ ID NO:
- 73), GQIQFPL(C) (SEQ ID NO:
- 95), GEIKFDH(C) (SEQ ID NO:
- 74), GEIQFGA(C) (SEQ ID NO:
- 75), QLPLFVL(C) (SEQ ID NO:
- 103), HQKMIF(C) (SEQ ID NO:
- 65), GELFFEK(C) (SEQ ID NO:
- 96), GEIRFEL(C) (SEQ ID NO:
- 97), AcGEIYFER(C) (SEQ ID NO:
- 105), SGEIYFER(C) (SEQ ID NO:
- 98), AGEIYFER(C) (SEQ ID NO:
- 99) and (C)GEIYFER (SEQ ID NO:
- 100).
A method of treating β-amyloidoses in an subject in need thereof, the method comprising administering to the subject at least one compound comprising a peptide having an amino acid sequence selected from the group consisting of SGEYVFH(C) (SEQ ID NO:
- 66), SGQLKFP(C) (SEQ ID NO:
- 67), SGQIWFR(C) (SEQ ID NO:
- 68), SGEIHFN(C) (SEQ ID NO:
- 69), GQIWFIS(C) (SEQ ID NO:
- 76), GQIIFQS(C) (SEQ ID NO:
- 77), GQIRFDH(C) (SEQ ID NO:
- 78), GEMWFAL(C) (SEQ ID NO:
- 79), GELQFPP(C) (SEQ ID NO:
- 80), GELWFP(C) (SEQ ID NO:
- 70), GEMQFFI(C) (SEQ ID NO:
- 81), GELYFRA(C) (SEQ ID NO:
- 82), GEIRFAL(C) (SEQ ID NO:
- 83), GMIVFPH(C) (SEQ ID NO:
- 84), GEIWFEG(C) (SEQ ID NO:
- 71), GQILFPV(C) (SEQ ID NO:
- 86), GELFFPK(C) (SEQ ID NO:
- 87), GQIMFPR(C) (SEQ ID NO:
- 88), GSLFFWP(C) (SEQ ID NO:
- 89), GEILFGM(C) (SEQ ID NO:
- 90), GQLKFPF(C) (SEQ ID NO:
- 91), GTIFFRD(C) (SEQ ID NO:
- 92), GQIKFAQ(C) (SEQ ID NO:
- 93), GTLIFHH(C) (SEQ ID NO:
- 94), GEIRFGS(C) (SEQ ID NO:
- 73), GQIQFPL(C) (SEQ ID NO:
- 95), GEIKFDH(C) (SEQ ID NO:
- 74), GEIQFGA(C) (SEQ ID NO:
- 75), GELFFEK(C) (SEQ ID NO:
- 96), GEIRFEL(C) (SEQ ID NO:
- 97), GEIYFER(C) (SEQ ID NO:
- 72), SGEIYFER(C) (SEQ ID NO:
- 98), AGEIYFER(C) (SEQ ID NO:
- 99) and (C)GEIYFER (SEQ ID NO:
- 100),
- wherein said compound having a binding capacity to an antibody which is specific for an epitope of the amyloid-beta-peptide (Aβ) comprising the amino acid sequence HQKLVF (SEQ ID NO:
- 57) and/or HQKLVFFAED (SEQ ID NO:
- 58).
Dependencies are inferred from the claim text.